Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) traded up 1.2% on Wednesday . The company traded as high as $155.38 and last traded at $155.16. 2,864,791 shares were traded during mid-day trading, a decline of 63% from the average session volume of 7,702,031 shares. The stock had previously closed at $153.25.
Analysts Set New Price Targets
A number of analysts have recently issued reports on JNJ shares. Bank of America boosted their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a research note on Wednesday, March 5th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Barclays boosted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $171.33.
Get Our Latest Report on JNJ
Johnson & Johnson Stock Performance
The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $385.33 billion, a PE ratio of 24.04, a P/E/G ratio of 2.56 and a beta of 0.47. The business's 50-day moving average price is $159.63 and its 200-day moving average price is $156.01.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Insider Buying and Selling at Johnson & Johnson
In related news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of JNJ. IFS Advisors LLC raised its position in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $33,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
